| Cat.No. | Name | Information |
|---|---|---|
| M2050 | GSK2636771 | GSK2636771 is a potent, orally available and specific PI3K p110β (PI3K beta, PI3Kβ) inhibitor. |
| M1925 | LY294002 | LY294002 is a highly selective PI3K inhibitor with IC50 values of 0.31, 0.73, 1.06 and 6.60 μM for PI3Kβ, PI3Kα, PI3Kδ and PI3Kγ respectively. LY294002 also inhibits CK2 with an IC50 of 98 nM. LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4 μM. |
| M2296 | 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM, respectively. |
| M1715 | GDC-0941 (Pictilisib) | GDC-0941 is a selective and potent inhibitor of Class I PI3K, p110a IC50=0.003uM, U87MG IC50=0.95μM. |
| M1984 | PF-04691502 | PF-04691502 is a potent and selective, ATP-competitive PI3K/mTOR inhibitor with IC50 of 7.5 nM and 3.8 nM of AKT T308 and AKT S473, respectively. |
| M2053 | Wortmannin (KY 12420) | Wortmannin (KY 12420) is a specific, covalent inhibitor of phosphatidylinositol 3-kinase (PI 3-kinase) with IC50 of 3 nM. |
| M1680 | BKM120 (Buparlisib) | BKM120 (NVP-BKM120) is a potent and highly specific oral pan-class I PI3K inhibitor. |
| M1819 | A66 | A66 is a potent and specific inhibitor of PI3K p110α with IC50 values of 32, 30 and 43 nM for p110α, p110α/E545K and p110α/H1047R. |
| M1671 | BEZ235 | BEZ235 (NVP-BEZ235) is a potent dual PI3K and mTOR inhibitor of p110α, p110γ, p110δ and p110β with IC50 of 4 nM, 5 nM, 7 nM and 75 nM, respectively. |
| M1773 | PI-103 | PI-103 is a potent, ATP-competitive PI3K,cell-permeable,inhibitor.The IC50 values are 2, 8, 20, 26, 48, 83, 88, 150 nM for DNA-PK, p110α, mTORC1, PI3-KC2β, p110δ, mTORC2, p110β, and p110γrespectively. |
| M3230 | D-87503 | D-87503 inhibits PI3K and Erk2 with IC50 of 62 nM and 760 nM, respectively. |
| M3218 | PKI-402 | PKI-402 is a potent dual pan-PI3K/mTOR inhibitor targeting PI3Kα/β/γ/δ and mTOR with IC50 of 2 nM/7 nM/16 nM/14 nM and 3 nM, respectively; also potent to PI3Kα mutants E545K and H1047R. |
| M3063 | TG100713 | TG100713 is a pan-PI3K inhibitor against PI3Kγ, PI3Kδ, PI3Kα and PI3Kβ with IC50 of 50 nM, 24 nM, 165 nM and 215 nM, respectively. |
| M3007 | SF1126 | SF1126 is the RGDS-conjugated precursor of LY294002 and the first-in-class dual PI3K/BRD4 pan-inhibitor with anti-tumor and anti-angiogenic activities. It also induces apoptosis. |
| M2609 | CZC24832 | CZC24832 is the first selective PI3Kγ inhibitor with IC50 of 27 nM, with 10-fold selectivity over PI3Kβ and >100-fold selectivity over PI3Kα and PI3Kδ. |
| M2567 | VS-5584 | VS-5584 (SB2343) is a potent and selective dual PI3K/mTOR inhibitor for mTOR, PI3Kα/β/δ/γ with IC50 of 3.4 nM and 2.6-21 nM, respectively. |
| M2436 | BAY 80-6946 | BAY 80-6946 (Copanlisib) is a potent and highly selective reversible PI3K inhibitor for PI3Kα/β with IC50 of 0.469 nM/3.72 nM. |
| M2295 | AZD6482 | AZD6482 is an inhibitor of PI3Kβ with IC50 of 21 nM. AZD6482 is particularly effective in blocking AKT signaling and tumor growth dependent on p110β activation or PTEN loss. |
| M2220 | GDC-0941 Bimesylate | GDC-0941 Bimesylate is the orally bioavailable bismesylate salt of a potent inhibitor of the class I phosphatidylinositol 3 kinase (PI3K). |
| M2135 | GDC-0032 | GDC-0032 is a potent, next generation PI3-kinase inhibitor. |
| M2073 | Duvelisib (IPI-145) | Duvelisib (IPI-145) is a potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. |
| M1978 | GSK1059615 | GSK1059615 is a potent, ATP-competitive inhibitor of PI 3-kinase alpha (PI3Kα) with IC50 of 2 nM. |
| M1945 | CAL-101 (Idelalisib) | CAL-101 (Idelalisib; GS-1101) is an oral PI3Kδ-specific inhibitor that has shown preclinical and clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. |
| M1933 | GNE-493 | GNE-493 is a potent, selective and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitor for the treatment of cancer. |
| M1931 | GSK2126458 | GSK2126458 is a highly potent inhibitor of phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) with low picomolar to subnanomolar activity. |
| M1896 | PIK-90 | PIK-90 is a novel and potent PI3K inhibitor with IC50 values of 11 nM, 350 nM, 18 nM and 58 nM for p110α, p110β, p110γ and p110δ respectively. |
| M1886 | TG100-115 | TG100-115 is a selective PI3K γ/δ inhibitor with IC50 values of 83 and 235 nM respectively. |
| M1879 | XL147 | XL147 (SAR245408) is an orally bioavailable, selective small molecule Class I PI3K kinase family inhibitor. |
| M1878 | ZSTK474 | ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3-kinase (PI3K), induces G1 arrest of the cell cycle in vivo. |
| M1849 | Voxtalisib (XL765) | Voxtalisib (SAR245409, XL765) is a dual inhibitor of mTOR/PI3K, mostly for p110γ with IC50 of 9 nM; also inhibits DNA-PK and mTOR. Phase 1/2. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
